Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
about
Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatmentTransplant-associated thrombotic microangiopathy: opening Pandora's box.New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.Renal dysfunction following bone marrow transplantation.Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis.Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies.Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.Hematopoietic cell transplantation in primary immunodeficiency - conventional and emerging indications.Thrombotic microangiopathy following haematopoietic stem cell transplant.A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma.Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD.Double trouble: Complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation.
P2860
Q28069228-AFC6C8B6-BE17-403E-A867-22E1CAEF2F92Q30235311-0F7FFE03-70D3-4F1A-A185-DA7AA16009D3Q33432069-8172B31B-B82D-40D4-8BC3-083A60629E88Q33435310-C44ABE8F-7FD7-4AAF-BB5F-83C6EF8399E6Q38907049-1127BAD8-CBDB-4790-9F49-ACEAA36DBF75Q38944989-DDF4F272-ADF5-4A47-80DE-0779FF2296B9Q39202357-94441C78-B8AE-4FF5-939C-C86E8066602AQ39677427-C174895F-DCB6-4519-A0CE-B3CC24F28F41Q40281926-FFD1491E-BBC7-48B6-B584-4023B903452AQ40722182-6FB73B4D-D256-4BC5-99CE-38B7C706308CQ41992358-258421C3-A0DB-4DD8-A8EF-5654BAE89A96Q47210347-AC61D7A1-D2B3-432F-A035-629FCFE3FFD4Q49375853-5F03F6B2-D82F-4C74-8CCC-EFB0BD721C7FQ49461578-891CC959-A350-4E57-B0CA-65B9980138F6Q50892145-A626D127-B44B-4FDB-83F7-71CFF814D3F0Q52774563-3E7376EE-5A77-449B-BAA3-D85563C57C1F
P2860
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Variable Eculizumab Clearance ...... tic Stem Cell Transplantation.
@ast
Variable Eculizumab Clearance ...... tic Stem Cell Transplantation.
@en
type
label
Variable Eculizumab Clearance ...... tic Stem Cell Transplantation.
@ast
Variable Eculizumab Clearance ...... tic Stem Cell Transplantation.
@en
prefLabel
Variable Eculizumab Clearance ...... tic Stem Cell Transplantation.
@ast
Variable Eculizumab Clearance ...... tic Stem Cell Transplantation.
@en
P2093
P2860
P50
P1476
Variable Eculizumab Clearance ...... etic Stem Cell Transplantation
@en
P2093
Ashley Teusink
Benjamin L Laskin
Bradley P Dixon
Danielle Lazear
Jens Goebel
Kana Mizuno
Kasiani C Myers
Ranjit S Chima
Russel Hirsch
Sonata Jodele
P2860
P304
P356
10.1016/J.BBMT.2015.10.002
P577
2015-10-09T00:00:00Z